← Human Trials & Peer-Reviewed Studies
Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease
Plain-language guide to PMID 23190934 (2012): clinical trial study of PACAP, parkinson's disease.
Key Facts
- PMID
- 23190934
- Journal
- CNS neuroscience & therapeutics
- Year
- 2012
- Study type
- Clinical Trial
- Authors
- Yin F et al. (8 authors)
- DOI
- 10.1111/cns.12025
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at PACAP in the context of parkinson's disease.
To assess the clinical effect of transplantation of human retinal pigment epithelial (hRPE) cells into the unilateral postcommissural putamen for treatment for Parkinson disease (PD).
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.
What Was Measured
The subject headings attached to it are Antigens, CD, Bucladesine, Carbon Isotopes, Cell Differentiation, Cells, Cultured, Cocaine and Dopamine Uptake Inhibitors.
What This Means in Plain Language
This is a clinical trial of PACAP in people with parkinson's disease.
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2012 (CNS neuroscience & therapeutics), a journal based in England.
More context: the PACAP compound page, Parkinson's disease research.
Our Notes on the Compound
PACAP: Pituitary adenylate cyclase-activating polypeptide, a 38-amino-acid neuropeptide studied in migraine provocation research.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.